High transcytosis of melanotransferrin (P97) across the blood–brain barrier

The blood–brain barrier (BBB) performs a neuroprotective function by tightly controlling access to the brain; consequently it also impedes access of proteins as well as pharmacological agents to cerebral tissues. We demonstrate here that recombinant human melanotransferrin (P97) is highly accumulated into the mouse brain following intravenous injection and in situ brain perfusion. Moreover, P97 transcytosis across bovine brain capillary endothelial cell (BBCEC) monolayers is at least 14‐fold higher than that of holo‐transferrin, with no apparent intra‐endothelial degradation. This high transcytosis of P97 was not related to changes in the BBCEC monolayer integrity. In addition, the transendothelial transport of P97 was sensitive to temperature and was both concentration‐ and conformation‐dependent, suggesting that the transport of P97 is due to receptor‐mediated endocytosis. In spite of the high degree of sequence identity between P97 and transferrin, a different receptor than the one for transferrin is involved in P97 transendothelial transport. A member of the low‐density lipoprotein receptor protein family, likely LRP, seems to be involved in P97 transendothelial transport. The brain accumulation, high rate of P97 transcytosis and its very low level in the blood suggest that P97 could be advantageously employed as a new delivery system to target drugs directly to the brain.

[1]  L. Fenart,et al.  Receptor-mediated Transcytosis of Lactoferrin through the Blood-Brain Barrier* , 1999, The Journal of Biological Chemistry.

[2]  W. Pardridge.  Blood-brain barrier biology and methodology. , 1999, Journal of neurovirology.

[3]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[4]  W. Jefferies,et al.  Transport and expression in human melanomas of a transferrin-like glycosylphosphatidylinositol-anchored protein. , 1994, The Journal of biological chemistry.

[5]  H. Kusuhara,et al.  Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). , 2001, Drug discovery today.

[6]  J. Brown,et al.  Identification of a cell surface protein, p97, in human melanomas and certain other neoplasms. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Pardridge,et al.  Combined Use of Carboxyl-Directed Protein Pegylation and Vector-Mediated Blood-Brain Barrier Drug Delivery System Optimizes Brain Uptake of Brain-Derived Neurotrophic Factor Following Intravenous Administration , 1998, Pharmaceutical Research.

[8]  I. Tamai,et al.  Carrier-mediated or specialized transport of drugs across the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[9]  B. Hyman,et al.  Elevation of LDL Receptor‐Related Protein Levels via Ligand Interactions in Alzheimer Disease and In Vitro , 2001, Journal of neuropathology and experimental neurology.

[10]  B. Carroll,et al.  Serum Melanotransferrin, p97 as a Biochemical Marker of Alzheimer's Disease , 2001, Neuropsychopharmacology.

[11]  W. Jefferies,et al.  Coincident expression and distribution of melanotransferrin and transferrin receptor in human brain capillary endothelium , 1996, Brain Research.

[12]  W. Pardridge,et al.  Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. , 1991, The Journal of pharmacology and experimental therapeutics.

[13]  W. Pardridge,et al.  Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin , 2001, Brain Research.

[14]  K. Hellström,et al.  Analysis of normal neoplastic human tissues for the tumor‐associated protein p97 , 1981, International journal of cancer.

[15]  W. Jefferies,et al.  Reactive microglia specifically associated with amyloid plaques in Alzheimer's disease brain tissue express melanotransferrin , 1996, Brain Research.

[16]  M. Brown,et al.  Low density lipoprotein receptor-related protein and gp330 bind similar ligands, including plasminogen activator-inhibitor complexes and lactoferrin, an inhibitor of chylomicron remnant clearance. , 1992, The Journal of biological chemistry.

[17]  W. Dreyer,et al.  Primary structure of the human melanoma-associated antigen p97 (melanotransferrin) deduced from the mRNA sequence. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Hussain,et al.  Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family. , 2001, Frontiers in bioscience : a journal and virtual library.

[19]  R. Doolittle,et al.  Human melanoma-associated antigen p97 is structurally and functionally related to transferrin , 1982, Nature.

[20]  J. Brown,et al.  Quantitative analysis of melanoma-associated antigen p97 in normal and neoplastic tissues. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[21]  M. Dehouck,et al.  Drug transfer across the blood-brain barrier: Correlation between “in vitro” and “in vivo” models , 1992, Neurochemistry International.

[22]  F. Real,et al.  Glycosyl phosphatidylinositol membrane anchoring of melanotransferrin (p97): apical compartmentalization in intestinal epithelial cells. , 1993, Journal of cell science.

[23]  M. Dehouck,et al.  Receptor-mediated transcytosis of transferrin through blood-brain barrier endothelial cells. , 1996, The American journal of physiology.

[24]  J. Tillement,et al.  Drug Transfer Across the Blood‐Brain Barrier: Correlation Between In Vitro and In Vivo Models , 1992 .

[25]  R. Béliveau,et al.  Purification and characterization of metabolically active capillaries of the blood-brain barrier. , 1991, The Biochemical journal.

[26]  H. Feldman,et al.  Serum levels of the iron binding protein p97 are elevated in Alzheimer′s disease , 1996, Nature Medicine.

[27]  A. Schwartz,et al.  RAP, a novel type of ER chaperone. , 1998, Trends in cell biology.

[28]  S. Loefas,et al.  Immobilization of proteins to a carboxymethyldextran-modified gold surface for biospecific interaction analysis in surface plasmon resonance sensors. , 1991, Analytical biochemistry.

[29]  D. Richardson,et al.  The membrane‐bound transferrin homologue melanotransferrin: roles other than iron transport? , 2000, FEBS letters.

[30]  INTERNATIONAL SOCIETY FOR NEUROCHEMISTRY , 1976 .

[31]  D. Holtzman,et al.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. , 2000, The Journal of clinical investigation.

[32]  D. Richardson.  The role of the membrane-bound tumour antigen, melanotransferrin (p97), in iron uptake by the human malignant melanoma cell. , 2000, European journal of biochemistry.

[33]  G. Bu,et al.  Receptor-associated Protein Is a Folding Chaperone for Low Density Lipoprotein Receptor-related Protein* , 1996, The Journal of Biological Chemistry.

[34]  U. Bickel,et al.  Delivery of peptides and proteins through the blood-brain barrier. , 1993, Advanced drug delivery reviews.

[35]  W. Jefferies,et al.  Melanotransferrin is produced by senile plaque-associated reactive microglia in Alzheimer's disease , 1999, Brain Research.

[36]  W. Pardridge,et al.  Binding and Internalization of Insulin and Insulin-Like Growth Factors by Isolated Brain Microvessels , 1986, Diabetes.

[37]  L. Fenart,et al.  A New Function for the LDL Receptor: Transcytosis of LDL across the Blood–Brain Barrier , 1997, The Journal of cell biology.

[38]  Christophe Rousselle,et al.  Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[39]  W. Pardridge,et al.  Capillary Depletion Method for Quantification of Blood–Brain Barrier Transport of Circulating Peptides and Plasma Proteins , 1990, Journal of neurochemistry.

[40]  T. Willnow.  Receptor-associated protein (RAP): a specialized chaperone for endocytic receptors. , 1998, Biological chemistry.

[41]  Yonghe Li,et al.  The Putative Tumor Suppressor LRP1B, a Novel Member of the Low Density Lipoprotein (LDL) Receptor Family, Exhibits Both Overlapping and Distinct Properties with the LDL Receptor-related Protein* , 2001, The Journal of Biological Chemistry.

[42]  H. Baker,et al.  Human melanotransferrin (p97) has only one functional iron‐binding site , 1992, FEBS letters.

[43]  R. Béliveau,et al.  Expression of multidrug‐resistance P‐glycoprotein (MDR1) in human brain tumors , 2001, International journal of cancer.